Fundamental Analysis of KYMERA THERAPEUTICS INC(NASDAQ:KYMR) stock

Fundamental Rating

Overall KYMR gets a fundamental rating of 3 out of 10. We evaluated KYMR against 587 industry peers in the Biotechnology industry. While KYMR seems to be doing ok healthwise, there are quite some concerns on its profitability. KYMR is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year KYMR has reported negative net income.

KYMR had a negative operating cash flow in the past year.

In the past 5 years KYMR always reported negative net income.

In multiple years KYMR reported negative operating cash flow during the last 5 years.

1.2 Ratios

The Return On Assets of KYMR (-25.53%) is better than 76.75% of its industry peers.

KYMR has a Return On Equity of -37.21%. This is in the better half of the industry: KYMR outperforms 76.92% of its industry peers.

		Industry Rank	Sector Rank
ROA	-25.53%
ROE	-37.21%
ROIC	N/A

ROA(3y)-22.58%

ROA(5y)-22.86%

ROE(3y)-30.2%

ROE(5y)-45.74%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

KYMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.

KYMR has more shares outstanding than it did 1 year ago.

The number of shares outstanding for KYMR has been increased compared to 5 years ago.

KYMR has about the same debt/assets ratio as last year.

2.2 Solvency

KYMR has an Altman-Z score of 6.18. This indicates that KYMR is financially healthy and has little risk of bankruptcy at the moment.

KYMR has a better Altman-Z score (6.18) than 81.54% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that KYMR is not too dependend on debt financing.

The Debt to Equity ratio of KYMR (0.00) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.18

ROIC/WACCN/A

WACC9.14%

2.3 Liquidity

A Current Ratio of 4.73 indicates that KYMR has no problem at all paying its short term obligations.

With a Current ratio value of 4.73, KYMR perfoms like the industry average, outperforming 51.97% of the companies in the same industry.

KYMR has a Quick Ratio of 4.73. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.

KYMR's Quick ratio of 4.73 is in line compared to the rest of the industry. KYMR outperforms 52.48% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.73
Quick Ratio	4.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.50% over the past year.

Looking at the last year, KYMR shows a very strong growth in Revenue. The Revenue has grown by 67.87%.

The Revenue has been growing by 32.18% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)12.5%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q58.33%

Revenue 1Y (TTM)67.87%

Revenue growth 3Y32.18%

Revenue growth 5YN/A

Revenue growth Q2Q196.69%

3.2 Future

KYMR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.03% yearly.

KYMR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.69% yearly.

EPS Next Y-24.26%

EPS Next 2Y-14.4%

EPS Next 3Y-12.15%

EPS Next 5Y5.03%

Revenue Next Year-15.4%

Revenue Next 2Y2.44%

Revenue Next 3Y0.54%

Revenue Next 5Y29.69%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

KYMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year KYMR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

KYMR's earnings are expected to decrease with -12.15% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-14.4%

EPS Next 3Y-12.15%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for KYMR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (5/6/2024, 10:08:43 AM)

37.78

+0.38 (+1.02%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.32B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-25.53%
ROE	-37.21%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.14

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.73
Quick Ratio	4.73
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)12.5%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-24.26%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)67.87%

Revenue growth 3Y32.18%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

KYMERA THERAPEUTICS INC (KYMR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens